Ignite Creation Date:
2025-12-24 @ 11:48 AM
Ignite Modification Date:
2026-03-26 @ 4:40 PM
Study NCT ID:
NCT05296161
Status:
RECRUITING
Last Update Posted:
2022-04-28
First Post:
2022-02-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
Sponsor:
Organization: